Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib Combined with Apatinib in Relapsed Ovarian Cancer
NCT04517357Phase 2Completed
- Sponsor
- Hengrui
- Start
- Oct 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Hengrui. Started Oct 2020; status: completed.
02
Drugs
fluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04517357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04517357.